Publications by authors named "T Devos"
Objectives: Identifying cardiac surgical patients at risk of requiring red blood cell (RBC) transfusion is crucial for optimizing their outcome. We critically appraised prognostic models preoperatively predicting perioperative exposure to RBC transfusion in adult cardiac surgery and summarized model performance.
Methods: Design: Systematic review and meta-analysis.
Article Synopsis
- * It found that stronger beliefs in equal childcare (both in what is considered normal and what should be the case) are associated with the availability of parental leave policies.
- * While the data suggests that changes in parental leave policies can shift perceptions of social norms over time, the study acknowledges that it cannot definitively determine cause-and-effect relationships due to its cross-sectional design.
Article Synopsis
- * An analysis of data from the SIMPLIFY-1 trial showed that momelotinib led to better outcomes, such as higher rates of transfusion independence and more stable transfusion needs, especially in patients with moderate to severe anemia (hemoglobin <12 g/dL).
- * Safety profiles for momelotinib remained consistent with previous findings, indicating that it offers benefits for spleen size, symptoms, and anemia for previously untreated patients, regardless of their baseline hemoglobin levels. *
Article Synopsis
- BCR::ABL1 negative myeloproliferative neoplasms (MPN) encompass a group of aggressive blood cancers, with primary myelofibrosis (PMF) showing the worst prognosis among them, leading to median survival rates of 16-35 months.
- A notable complication of MPN is the progression to secondary acute myeloid leukemia (AML), which carries an even worse prognosis than de novo AML, highlighting the need for better understanding and treatment options.
- The study focuses on the role of the cytokine CXCL8 and its receptor (CXCR1/2) in PMF pathogenesis, indicating that higher levels of CXCL8 correspond to lower survival rates, and suggests new therapeutic
Article Synopsis
- Bone marrow fibrosis (BMF) is linked to myelofibrosis and can affect prognosis, but this study explores its relationship with treatment outcomes in patients receiving JAK inhibitors momelotinib and ruxolitinib.
- In a study of patients with BMF, only momelotinib showed increased transfusion independence and hemoglobin levels, while ruxolitinib showed a decrease in hemoglobin.
- The findings suggest that changes in BMF do not correlate with clinical improvements or survival benefits, indicating that BMF may not be an effective surrogate marker for assessing the efficacy of JAK inhibitors.